STE:NYE-STERIS plc (USD)

EQUITY | Medical Devices | New York Stock Exchange

Last Closing

USD 242.54

Change

+3.49 (+1.46)%

Market Cap

USD 5.64B

Volume

0.53M

Analyst Target

USD 175.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

STERIS PLC is a provider of infection prevention and other procedural products and services, focused on healthcare, pharmaceutical and research.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-30 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
ABT Abbott Laboratories

+1.58 (+1.41%)

USD 198.37B
MDT Medtronic PLC

+0.71 (+0.79%)

USD 115.25B
ZBH Zimmer Biomet Holdings Inc

-0.27 (-0.25%)

USD 22.04B
SNN Smith & Nephew SNATS Inc

+0.02 (+0.06%)

USD 13.37B
GMED Globus Medical

+0.93 (+1.32%)

USD 9.55B
BIO-B Bio-Rad Laboratories Inc

N/A

USD 9.22B
BIO Bio-Rad Laboratories Inc

+2.81 (+0.85%)

USD 9.22B
PEN Penumbra Inc

+2.76 (+1.44%)

USD 7.80B
GKOS Glaukos Corp

+1.99 (+1.55%)

USD 7.05B
INSP Inspire Medical Systems Inc

+8.57 (+4.23%)

USD 6.35B

ETFs Containing STE

EVX VanEck Environmental Serv.. 0.00 % 0.56 %

+0.82 (+0%)

N/A
HIG:CA Global Healthcare Income .. 0.00 % 1.02 %

+0.02 (+0%)

CAD 0.05B
HIG-U:CA 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 10.32% 63% D 56% F
Dividend Return 0.73% 36% F 11% F
Total Return 11.05% 60% D- 50% F
Trailing 12 Months  
Capital Gain 12.55% 50% F 42% F
Dividend Return 0.99% 36% F 11% F
Total Return 13.54% 50% F 37% F
Trailing 5 Years  
Capital Gain 74.48% 73% C 78% C+
Dividend Return 6.45% 31% F 19% F
Total Return 80.92% 77% C+ 76% C+
Average Annual (5 Year Horizon)  
Capital Gain 11.60% N/A N/A 71% C-
Dividend Return 12.53% N/A N/A 68% D+
Total Return 0.92% N/A N/A 21% F
Risk Return Profile  
Volatility (Standard Deviation) 18.91% N/A N/A 54% F
Risk Adjusted Return 66.24% N/A N/A 81% B-
Market Capitalization 5.64B 91% A- 91% A-

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Devices) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 32.50 50% 16%
Price/Book Ratio 3.71 34% 24%
Price / Cash Flow Ratio 24.22 29% 12%
Price/Free Cash Flow Ratio 18.56 29% 20%
Management Effectiveness  
Return on Equity 8.97% 88% 56%
Return on Invested Capital 8.10% 81% 61%
Return on Assets 5.52% 84% 78%
Debt to Equity Ratio 49.51% 45% 60%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.